AN OPTOCHEMICAL SENSOR, AND USES THEREOF
    2.
    发明公开

    公开(公告)号:EP4231010A1

    公开(公告)日:2023-08-23

    申请号:EP22157103.7

    申请日:2022-02-16

    IPC分类号: G01N31/22 G01N21/64 G01N21/77

    摘要: An optochemical sensor comprises a substrate coated with a solid-state optically active pH-sensitive material comprising a hydrophobic plasticised polymer matrix, a protonable photoluminescent dye selected from the group consisting of a hydrophobic metal-free porphyrin and a porphyrin-ketone, and a hydrophobic proton transfer reagent, in which the hydrophobic proton-transfer reagent comprises a salt of a fluorinated derivative of tetraphenylborate. The salt of the substituted tetraphenylborate derivative is selected from a salt of tetrakis[3,5-bis(trifluoromethyl)phenyl]borate and a salt of tetrakis-(pentafluorophenyl)borate. The hydrophobic polymer comprises poly(n-butylacrylate) or poly(vinylchloride) and a suitable plasticiser. The use of substituted fluorinated TCPB analogues, in particular sodium salt of tetrakis[3,5-bis(trifluoromethyl)phenyl]borate, as a proton transfer agent (PTA), is seen to have excellent solubility in plasticised PVC and poly(n-butylacrylate) matrices and low cytotoxic action on cells. Moreover, by changing the concentration of this PTA in the sensor, one can tune the sensor pKa values and measured range of pH values, to cover the most important physiological range of pH (7.5 - 6.0) and ECA rates.

    INTRACORONARY INFUSION OF IGF-1 FOR MYOCARDIAL REPAIR
    9.
    发明授权
    INTRACORONARY INFUSION OF IGF-1 FOR MYOCARDIAL REPAIR 有权
    IGF-1在心脏修复中的应用

    公开(公告)号:EP3047861B1

    公开(公告)日:2017-10-18

    申请号:EP16152830.2

    申请日:2009-11-27

    发明人: Caplice, Noel

    IPC分类号: A61L29/04 A61L29/16

    摘要: Provided herein are methods for treating an individual having (suffering from) an acute myocardial infarction and drug eluting stents useful for treating such individuals. These methods include treating an individual by introducing, such as by surgically inserting, at a site of an acute coronary artery occlusion upstream of the site of acute myocardial infarction, a drug eluting stent (DES) that is capable of eluting from 25pg to 950pg of IGF-1 directly into the coronary circulation. The treatment is specifically directed to stimulation of repair or survival of damaged cardiac muscle or left ventricular remodeling.